Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme.
| Date | Est. | Actual | |
|---|---|---|---|
| May 15, 2025 | – | -$0.30 | |
| Apr 8, 2025 | -$0.24 | $0.01 | Beat |
| Dec 23, 2024 | -$0.19 | -$0.20 | Miss |
| Sep 13, 2024 | -$0.22 | -$0.63 | Miss |
| Apr 15, 2024 | -$0.15 | -$0.53 | Miss |
| Feb 28, 2024 | -$0.19 | -$0.62 | Miss |